Nemolizumab Chemical Properties

storage temp. 

Store at -20°C

form 

Liquid

color 

Colorless to light yellow

Nemolizumab Usage And Synthesis

Uses

Nemolizumab (CIM331) is a humanized monoclonal antibody that targets the human interleukin-31 receptor a, preventing interleukin-31 (IL-31) from binding to its receptor and the subsequent signaling. Nemolizumab can help reduce itching and sleep disturbances, and it is being studied for atopic dermatitis (AD)[1][2].

in vivo

References

[1] Nakahara T, et, al. Nemolizumab and Atopic Dermatitis: the Interaction Between Interleukin-31 and Interleukin-31 Receptor as a Potential Therapeutic Target for Pruritus in Patients With Atopic Dermatitis. 2018;5:405–14.
[2] O Nemoto, et al. The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study. Br J Dermatol. 2016 Feb;174(2):296-304. DOI:10.1111/bjd.14207
[3] Oyama S, et al. Cynomolgus monkey model of interleukin-31-induced scratching depicts blockade of human interleukin-31 receptor A by a humanized monoclonal antibody. Exp Dermatol. 2018 Jan;27(1):14-21. DOI:10.1111/exd.13236

Nemolizumab(1476039-58-3)Related Product Information

• Zolimomabaritox
• Ocaratuzumab
• Radretumab
• Frunevetmab
• Crovalimab
• Tarcocimab
• Fianlimab
• Vanucizumab
• Axatilimab
• Murlentamab